string: Middle and upper levels aim to capture effects of the £20,000–30,000 threshold range quoted in AWMSG process documentation [19]
  Uncertainty in cost
  effectiveness is thoroughly explored (UNCERTAINTY)
  This indicates whether or not the degree of uncertainty
  in cost-effectiveness estimates has been explored by assessing the combined uncertainty arising from several data sources (known as PSA)
  Effects coded:
  Yes 1, No -1 Attribute: AWMSG appraisal guideline makes specific reference to uncertainty in cost-effectiveness
  estimates [19]
  Levels: Reporting of PSA was found to influence AWMSG/NMG recommendations in an RP study
  [10]
  AWMSG All Wales Medicines Strategy Group, CUA cost-utility analysis, HR-QOL health-related quality of life, ICER incremental cost-effectiveness ratio, NICE National Institute for Health and Clinical Excellence, NMG New Medicines Group, PSA probabilistic sensitivity analysis, QALY quality-adjusted life-year, RP revealed preference, SP stated preference
  accommodates multiple selections among the alternatives (e.g. both new medicine A and new medicine B), was employed to analyse responses to the secondary flexiblechoice questions.